Thermographic evaluation of piroxicam’s effect as an adjuvant treatment in canine mammary tumors
DOI:
https://doi.org/10.33448/rsd-v10i2.12236Keywords:
Canine; Oncology; Inflammation; Mammary Gland; COX-2 Inhibitors.Abstract
Mammary tumors are the second most diagnosed neoplasms in dogs. Canine females are largely affected by malignant mammary tumours. Several factors are involved in the development and determination of the malignancy of these lesions, including the action of cyclooxygenase-2. Use of non-steroidal anti-inflammatory drugs as enzyme-inhibiting drugs has been studied as a promising adjuvant treatment for neoplasms. The aim of this study was to evaluate the effect of piroxicam in reducing inflammation caused by mammary tumours in 25 bitches during 10 days of administration based on the measurement of peritumoral temperature using thermography. The results indicated a significant difference (p=0,003) between the average temperatures at the first and last day of treatment. When performing the evaluation of malignant and benign neoplasms separately, it was possible to observe that, statistically, malignant neoplasms (n=19) showed a significant reduction in peritumoral temperatures (P=<0.001), however, benign neoplasms (n=6) have not obtained a significant difference in temperature after the therapeutic protocol (P=0.954). Therefore, it was possible to demonstrate the efficacy of the medication in reducing the heat caused by inflammation and allowing advances in the development of therapeutic protocols for mammary tumors in bitches, such as the inclusion of the drug in the period prior to the mastectomy surgeries.
References
Anadol, E., Saglam, A. S. Y., Gultiken, N., Karakas, K., Alcigir, E., Alkan, H., & Kanca, H. (2017). Expression of iNOS, COX-2 and VEGF in canine mammary tumours and non-neoplastic mammary glands: association with clinicopatholgical features and tumour grade. Acta Veterinaria Hungarica, 65(3), 382-393.
Cassali, G. D., Jark, P. C., Gamba, C., Damasceno, K. A., Estrela-Lima, A., De Nardi, A. B., Ferrerira, E., Horta, R. S., Firmo, B. F., Sueiro, F. A. R., Rodrigues, L. C. S., & Nakagaki, K. Y. R. (2019). Consensus regarding the diagnosis, prognosis and treatment of canine and feline mammary tumors. Brazilian Journal of Veterinary Pathology, 13(3), 555-574.
Carvalho, M. I., Pires, I., Prada, J., Raposo, T. P., Gregório, H., Lobo, L., & Queiroga, F. L. (2016). High COX-2 expression is associated with increased angiogenesis, proliferation and tumoural inflammatory infiltrate in canine malignantmammary tumours: a multivariate survival study. Veterinary and Comparative Oncology, 15(2),619-631.
De Nardi, A. B., Ferreira, T. M. M. R., & Assunção, K. A. (2016). Neoplasias Mamárias. In A. B. De Nardi & C. R. Daleck. Oncologia em cães e gatos (pp. 499-515). Rio de Janeiro: Roca.
Doré, M. (2011). Cyclooxygenase-2 expression in animal cancers. Veterinary Pathology, 48(1), 254-265.
Heller, D. A., Clifford, C. A., Goldschmidt, M. H., Holt, D. E., Shofer, F. S., Smith, A. & Sorenmo K. (2005). Cyclooxygenase-2 expression in associated with histologic tumor type in canine mammary carcinoma. Veterinary Pathology, 42(6), 776-780.
Henry, C. J. (2012). The Etiology of Cancer - Section B: Chemical, Physical, and Hormonal Factors. In S. J. Withrow, D. M. Vail, & R. L. Page. Withrow & MacEwen`s Small Animal Clinical Oncology (pp. 1-29). Saunders.
Liu, C. H., Chang, S. H., Narko, K., Trifan, O. C., Wu, M. T., Smith, E., Haudenschild, C., Lane, T. F., & Hla, T.(2001). Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. Journal of Biological Chemestry, 276(21), 18563–18569.
Pavelski, M., Silva, D. M., Leite, N. C., Junior, D. A., De Sousa, R. S., Guerios, S. D., & Dornbusch, P. T. (2015). Infrared Thermography in Dogs with Mammary Tumors and Healthy Dogs. Journal of Veterinary Internal Medicine, 29(6), 1578-1583.
Queiroga, F. L., Pires, I., Parente, M., Gregório, H., & Lopes, C. (2011). COX-2 over-expression correlates with VEGF and tumour angiogenesis in canine mammary cancer. The Veterinary Journal, 189(1),77-82.
Rang, H. P., Ritter, J. M., Flower, R. J., & Henderson, G. (2016a). Mecanismos celulares: defesa do hospedeiro. In H. P. Rang, J. M. Ritter, R. J. Flower, & G. Henderson. Rang & Dale: Farmacologia (209-236). São Paulo: Elsevier.
Rang, H. P., Ritter, J. M., Flower, R. J., & Henderson, G. (2016b). Fármacos anti-inflamatórios e imunossupressores. In H. P. Rang, J. M. Ritter, R. J. Flower, & G. Henderson. Rang & Dale: Farmacologia (754-794). São Paulo: Elsevier.
Roberto, J. V. B., & Souza, B. B. (2014) Utilização da termografia de infravermelho na medicina veterinária e na produção animal. Journal of Animal Behaviour and Biometeorology, 2(3), 73-84.
Rodaski, S., & De Nardi, A. B. (2008). Quimioterapia antineoplásica em cães e gatos. São Paulo: MedVet Livros.
Salvador, R. C. L., Terra, E. M., Raposo, T. M. M., Alves, C. E. F., Costa, M. .T., & Amorim, R. L. (2013) Increased cycloxygenase-2 (COX-2) expression in associated with the progression and aggression of canine mammary tumors. Archives of Veterinary Science, 18(2), 205-207.
Souza, C. H. M., Toledo-Piza, E., Amorin, R., Barboza, A., & Tobias, K. M. (2009). Inflammatory mammary carcinoma in 12 dogs: Clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment. Canadian Veterinary Journal, 50(5), 506-510.
Tedardi, M. V., Kimura, K. C., Mendonça, P. P., & Dagli, M. L. Z. (2016). Epidemiologia e Etiologia do Câncer. In A. B. De Nardi, & Daleck, C. R. Oncologia em cães e gatos (pp. 1-28). Rio de Janeiro: Roca.
Szweda, M., Rychlik, A., Babinska, I., & Pomianowski, A. (2020). Cyclooxygenase-2 as a biomarker with diagnostic, therapeutic, prognostic, and predictive relevance in small animal oncology. Journal of Veterinary Research, 64(1), 151-160.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Julia Rodrigues Greghi; Maíra Planzo Fernandes, Aline Groth, Letícia Amanda dos Santos Silva, Josiana de Fátima Schnitzer, Giovana Wingeter Di Santis, Maria Isabel Mello Martins
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.